Thermo Fisher Scientific (TMO) Other financing activities (2009 - 2026)

Thermo Fisher Scientific has disclosed Other financing activities across 18 years of filings, most recently posting $39.0 million for Q1 2026.

• Quarterly Other financing activities fell 13.33% year-over-year to $39.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $84.0 million (down 35.38% YoY) and the FY2025 annual result came in at $90.0 million, down 53.85% from the prior year.
• Other financing activities eased to $39.0 million in Q1 2026, from $91.0 million in the prior quarter.
• Over five years, Other financing activities peaked at $110.0 million in Q1 2024 and troughed at -$42.0 million in Q2 2025.
• A 5-year average of $21.8 million and a median of $20.0 million in 2022 frame the typical range for Other financing activities.
• Annual changes were most pronounced in 2022 — Other financing activities plunged 270.0% — and 2024, when it jumped 775.0%.
• Tracing TMO's Other financing activities over 5 years: stood at $20.0 million in 2022, then decreased by 30.0% to $14.0 million in 2023, then sank by 221.43% to -$17.0 million in 2024, then jumped by 635.29% to $91.0 million in 2025, then tumbled by 57.14% to $39.0 million in 2026.
• Business Quant data shows TMO's Other financing activities at $39.0 million in Q1 2026, $91.0 million in Q4 2025, and -$4.0 million in Q3 2025.